Cencora Stock News

Cencora, Inc. (NYSE:COR ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 11:30 AM EDT Company Participants James Cleary - Executive VP & CFO Bennett Murphy - Senior VP, Head of Investor Relations & Treasury Conference Call Participants Erin Wilson Wright - Morgan Stanley, Research Division Presentation Erin Wilson Wright Equity Analyst Good afternoon, everyone. Welco...

Cencora, Inc. (NYSE:COR ) Baird Global Healthcare Conference 2025 September 9, 2025 3:45 PM EDT Company Participants Bennett Murphy - Senior VP, Head of Investor Relations & Treasury James Cleary - Executive VP & CFO Conference Call Participants Eric Coldwell - Robert W. Baird & Co. Incorporated, Research Division Presentation Eric Coldwell Senior Research Analyst All right.

Cencora, Inc. (NYSE:COR ) Wells Fargo 20th Annual Healthcare Conference 2025 September 5, 2025 8:45 AM EDT Company Participants James Cleary - Executive VP & CFO Bennett Murphy - Senior VP, Head of Investor Relations & Treasury Conference Call Participants Stephen Baxter - Wells Fargo Securities, LLC, Research Division Presentation Stephen Baxter Senior Equity Analyst All right. Good morning, e...

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has appointed Lead Independent Director D. Mark Durcan as Chairman of the Board of Directors, effective October 1, 2025. Mr. Durcan will succeed Steven H. Collis, who has served as Cencora's Chairman since 2016 and previously served as Cencora's Chief Executive Officer from 2011 until 2024....

Cencora delivered strong quarterly results and guidance upgrades, but expectations need to be moderated as these results should fade in the coming quarters. The valuation remains elevated at 17.9x forward P/E, well above the 5-year average, making the risk/reward unattractive at current levels. Key risks include heavy revenue exposure to Walgreens Boots Alliance, which faces solvency issues and...

I initiate Cencora, Inc. with a Buy rating and a fair value of $337, due to its stable business model and strategic specialty drug expansion. Cencora's acquisition of Retina Consultants of America and focus on GLP-1 drugs strengthen its specialty solutions, supporting long-term growth and margin improvement. Management's commitment to digital infrastructure and specialty expertise positions Cen...

Cencora, Inc. (NYSE:COR ) Q3 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants Bennett S. Murphy - Senior VP, Head of Investor Relations & Treasury James F.

U.S. drug distributor Cencora raised its annual profit forecast on Wednesday after posting quarterly earnings that topped Wall Street estimates, buoyed by surging demand for specialty therapies and blockbuster weight-loss drugs.